| 0 (0%) | 12-05 09:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.52 | 1-year : | 2.83 |
| Resists | First : | 2.15 | Second : | 2.42 |
| Pivot price | 1.85  |
|||
| Supports | First : | 1.73 | Second : | 1.43 |
| MAs | MA(5) : | 1.92  |
MA(20) : | 1.88 |
| MA(100) : | 2.01 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.3 |
D(3) : | 46.2 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 2.63 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IPHA ] has closed below upper band by 25.0%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.95 - 1.96 | 1.96 - 1.97 |
| Low: | 1.87 - 1.88 | 1.88 - 1.89 |
| Close: | 1.89 - 1.91 | 1.91 - 1.93 |
Thu, 04 Dec 2025
Why IPHA stock could see breakout soon - Wall Street Watch & Capital Efficient Trade Techniques - Newser
Fri, 28 Nov 2025
Innate Pharma (NASDAQ: IPHA) reports 92,962,943 theoretical voting rights on Nov. 27 - Stock Titan
Mon, 10 Nov 2025
Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacut - GuruFocus
Mon, 10 Nov 2025
Innate Pharma (NASDAQ: IPHA) cleared to start TELLOMAK 3 in CTCL, first half 2026 - Stock Titan
Mon, 10 Nov 2025
IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers - Stocktwits
Thu, 06 Nov 2025
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 92 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 221 (K) |
| Shares Short P.Month | 53 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | -523.2 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -271.4 % |
| Qtrly Rev. Growth | -60.6 % |
| Gross Profit (p.s.) | -0.34 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -2.99 |
| PEG Ratio | 0 |
| Price to Book value | 31.83 |
| Price to Sales | 13.92 |
| Price to Cash Flow | -4.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|